|
EPO906 Therapy in Patients with Advanced Breast Cancer Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, trips or professional assistance with a real medical doctor. We aren't docs. Always confer with your doctor about EPO906 Therapy in Patients with Advanced Breast Cancer conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. EPO906 Therapy in Patients with Advanced Breast Cancer Clinical research trials and EPO906 Therapy in Patients with Advanced Breast Cancer health trials happen in many of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the effectualness of new does drugs. The intention of the studies / projects is to figure out particular human healthcare questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to detect cures for all forms of circumstances, like EPO906 Therapy in Patients with Advanced Breast Cancer. EPO906 Therapy in Patients with Advanced Breast Cancer Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment options before they are available to the general public. Most times the subjects get treatment for free of charge, and occasionally they are paid for their time. Occasionally there is a cost for a EPO906 Therapy in Patients with Advanced Breast Cancer clinical trial. Subjects frequently get the best healthcare possible for their EPO906 Therapy in Patients with Advanced Breast Cancer condition. Hazards are a reality, however, and could include more or frequent mD visits, health risks (possibly life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "E" Clinical Trials Conditions > EPO906 Therapy in Patients with Advanced Breast Cancer  EPO906 Therapy in Patients with Advanced Breast Cancer
EPO906 Therapy in Patients with Advanced Breast Cancer
For Condition: Breast Neoplasms
Status: Suspended
Sponsor(s): Novartis Pharmaceuticals ,
Synopsis: This study will examine whether the investigational drug EPO906, given by intravenous infusion (IV directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause breast cancer.
Details:
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study
Minimum Age/Maximum Age: 18 Years/85 Years
Genders: Female
Protocol Entry Criteria: Inclusion Criteria The following patients may be eligible for this study: - Histologically or cytologically documented evidence of disease with at least one measurable lesion; - Life expectancy of greater than three (3) months; - Patients who have had only one prior therapy for metastatic disease; - Patients who have received prior treatment with hormonal agents or who have had prior treatment regimens of radiotherapy in addition to one or no previous chemotherapy regimens are eligible; - Patients who have had no prior therapy for metastatic disease, but who have received a taxane and an anthracycline (single or combination therapy) as adjuvant treatment, are eligible. For patients who have had previous radiation therapy to the target lesion(s), the lesion(s) must since have demonstrated progression. Exclusion Criteria The following patients are not eligible for this study: - Bone-only disease; - Symptomatic pleural effusions; - Symptomatic CNS metastases or leptomeningeal involvement; - Any peripheral neuropathy or unresolved diarrhea greater than Grade 1; - Severe cardiac insufficiency; - Patients taking Coumadin or other warfarin-containing agents with the exception of low dose Coumadin (1 mg or less) for the maintenance of in-dwelling lines or ports; - History of another malignancy within 5 years prior to study entry except curatively treated non-melanoma ckin cancer or cervical cancer in situ; - Active or suspected acute or chronic uncontrolled infection including abcesses or fistulae; - HIV+ patients; - Pregnant or lactating females; - Patients who have had radiation, chemotherapy, or hormonal therapy within the last four (4) weeks excluding palliative radiotherapy to isolated peripheral bone metastases not being used as markers for efficacy; - Patients taking Herceptin less than three (3) weeks prior to study start.
Total Enrollment: 48
Location and Contact Information:
Cancer Institute of New Jersey (CINJ)
New Brunswick, New Jersey, 08901
United States
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, 03756
United States
Additional Information:
Study ID Numbers: CEPO906A-2205;
Study Start Date:
Record last reviewed: December 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00035126
Other Breast Neoplasms Studies:
1. Removal of the ovaries/fallopian tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic Risk
2. Analysis of Brain Metastasis in Patients with Breast Cancer, with and without Over-Expression of HER-2
3. Phase II Study to Evaluate Tariquidar (XR9576), a Selective MDR-1 Inhibitor, in Chemotherapy Resistant Advanced Breast Cancer
4. Study to Evaluate the Efficacy, Safety, and Tolerability of E7070 in Metastatic Breast Cancer Patients
5. Breast Neoplasms Study
Related Studies:
Other Breast Neoplasms Clinical Trials
Other New Jersey Clinical Trials
Other New Brunswick Clinical Trials
EPO906 Therapy in Patients with Advanced Breast Cancer
|
|
|
|
|
|
|
|
